{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-013781","form_type":"8-K","ticker":"RNXT","cik":"0001574094","company_name":"RenovoRx, Inc.","filed_at":"2023-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.469916+00:00","generated_at":"2026-06-16T08:57:36.522772+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"RenovoRx appoints former Schering-Plough CMO Robert Spiegel to board","bullets":["Dr. Spiegel appointed as independent director effective April 25, 2023; board size increased from 6 to 7.","He brings 40+ years biopharma experience, involved in over 30 FDA NDA approvals and multiple blockbuster drugs.","Received initial option award for 43,026 shares valued at $120,000, vesting monthly over 36 months.","Company plans to advance FDA discussions on RenovoGem Phase III interim data and new indications.","Dr. Spiegel also serves on boards of Geron, Cyclacel, Ayala, Athenex, and SPARC."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-013781","json":"https://secwatch.observer/filing/0001493152-23-013781.json","markdown":"https://secwatch.observer/filing/0001493152-23-013781.md","text":"https://secwatch.observer/filing/0001493152-23-013781.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574094/000149315223013781/0001493152-23-013781-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574094/000149315223013781/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T08:57:36.522772+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b2d2054263","claim":"Robert Spiegel was appointed as independent director at RenovoRx, Inc..","evidence_excerpt":"Effective as of April 25, 2023, the Board of Directors of RenovoRx, Inc. (the “Company”) appointed Robert Spiegel, M.D., FACP, to its Board of Directors as an independent director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1574094/000149315223013781/0001493152-23-013781-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"independent director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}